Using programmed death-1 (PD-1) inhibitors in the treatment of metastatic non-small cell lung cancers (NSCLC) at Heart of England NHS Foundation Trust (HEFT)

Powell R. L.; Kussaibati R.; Baijal S.

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Using programmed death-1 (PD-1) inhibitors in the treatment of metastatic non-small cell lung cancers (NSCLC) at Heart of England NHS Foundation Trust (HEFT)

【24h】

Using programmed death-1 (PD-1) inhibitors in the treatment of metastatic non-small cell lung cancers (NSCLC) at Heart of England NHS Foundation Trust (HEFT)

机译：使用编程的死亡-1（PD-1）抑制剂在英国NHS基金会信托（HEFT）的中心治疗转移性非小细胞肺癌（NSCLC）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2018年第2018期|共2页
作者
Powell R. L.; Kussaibati R.; Baijal S.;
展开▼
作者单位

Heart England NHS Fdn Trust Oncol Birmingham W Midlands England;

Heart England NHS Fdn Trust Oncol Birmingham W Midlands England;

Heart England NHS Fdn Trust Oncol Birmingham W Midlands England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Using programmed death-1 (PD-1) inhibitors in the treatment of metastatic non-small cell lung cancers (NSCLC) at Heart of England NHS Foundation Trust (HEFT) [J] . Powell R. L., Kussaibati R., Baijal S. Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第Suppla1期

机译：使用编程的死亡-1（PD-1）抑制剂在英国NHS基金会信托（HEFT）的中心治疗转移性非小细胞肺癌（NSCLC）
2. Using programmed death-1 (PD-1) inhibitors in the treatment of metastatic non-small cell lung cancers (NSCLC) at Heart of England NHS Foundation Trust (HEFT) [J] . Powell R. L., Kussaibati R., Baijal S. Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第期

机译：使用编程的死亡-1（PD-1）抑制剂在英国NHS基金会信托（HEFT）的中心治疗转移性非小细胞肺癌（NSCLC）
3. Using programmed death-1 (PD-1) inhibitors in the treatment of metastatic non-small cell lung cancers (NSCLC) at Heart of England NHS Foundation Trust (HEFT) [J] . Powell R. L., Kussaibati R., Baijal S. Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第Suppla1期

机译：使用编程的死亡-1（PD-1）抑制剂在英国NHS基金会信托（HEFT）的中心治疗转移性非小细胞肺癌（NSCLC）
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors [O] . Misako Nagasaka, Nadine Abdallah, Marcus Crosby, 2019

机译：回顾性研究评估非小细胞肺癌（NSCLC）中的治疗前肿瘤体积（PTV）作为对程序死亡1（PD-1）抑制剂反应的预测因子
7. PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors [O] . Foteinos-Ioannis Dimitrakopoulos, Achilleas Nikolakopoulos, Anastasia Kottorou, 2020

机译：PIO（Patras免疫疗法评分）得分与抗议细胞死亡-1（PD）治疗的先进的非小细胞肺癌（NSCLC）患者的最佳整体反应，无进展生存和免疫治疗的总生存相关（PD -1）抑制剂

Using programmed death-1 (PD-1) inhibitors in the treatment of metastatic non-small cell lung cancers (NSCLC) at Heart of England NHS Foundation Trust (HEFT)

著录项

相似文献

相关主题

期刊订阅